Project Grant W81XWH1510616

Grant Award Summary Gavia Bio, LLC received a $314,363 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 5, 2025, with a completion date of August 31, 2026. The award funds Phase I preclinical development of DGL13K, a patented antimicrobial peptide designed as a novel topical treatment for drug-resistant burn wound infections. The project addresses a critical clinical...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...

The federal Cooperative Agreement award of $1,853,685.00 from the Uniformed Services University of Health Sciences, under the Uniformed Services University Medical Research Projects program (CFDA 12.750), supports the development of a broad-spectrum combination antibacterial therapy with a metallo beta-lactamase inhibitor against multi-drug resistant (MDR) wound infections. The prime awardee, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., will work with a...

This $2,134,174 Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the Metis Foundation supports the development of a "sprayable antimicrobial and regeneration promoting foam scaffold for the treatment of non-healing skin wounds." The grant has an award date of September 1, 2023 and a completion date of August 31, 2027. The Metis Foundation, a non-profit organization that supports innovative medical research and education for...

Grant Award Summary Halomine Inc., doing business as Avantguard, received a $299,435 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded August 1, 2025, with completion scheduled for July 31, 2026. The grant supports the development and optimization of a novel, bio-inspired stabilized chloramine formulation designed to treat cutaneous fungal infections, particularly tinea (ringworm),...

The National Science Foundation (NSF) awarded a $451,276 Project Grant to the University of Texas at Arlington (UTA) under the Mathematical and Physical Sciences (MPS) program (CFDA 47.049) for the project "Design of pH-Responsive Peptide Assembly for Acid-Activatable Antimicrobial Therapy." The project aims to develop self-assembling antimicrobial nanofibers that are activated in acidic environments, such as those found in infections, to effectively kill antibiotic-resistant...

This federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support the "DEVELOPMENT OF INNOVATIVE THERAPEUTICS AGAINST PRESSURE ULCER-ASSOCIATED BACTERIA" at New York University School of Medicine. The $1,695,467.00 award, active from August 15, 2023 to August 14, 2027, will fund research to develop innovative treatments against bacteria associated with pressure ulcers. As a private...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will fund the development of an advanced wound care product to treat diabetic foot ulcers. The $305,000 award to Therapeutic Bandage Products, Inc. will support the creation of a patented microneedle bandage that delivers three therapeutic agents to disinfect the wound, prevent bacterial biofilm formation, and attract white blood cells to aid healing. This...

This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to assess the developability and in vivo pharmacology of AQP9 inhibitors for treating systemic inflammation caused by burn wounds. The total award amount is $1,634,902.00, with a period of performance from November 1, 2024 to October 31, 2026. The primary work under this grant will be conducted by the University of Florida, a major public...

The University of Memphis was awarded a $268,156 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of March 15, 2021 through March 14, 2024. The grant funding will support the development of acylated nanofibrous chitosan membranes for pre-hospital traumatic wound coverage, inhibition of infection, and pain mitigation. Specifically, the University of Memphis will work to transform battlefield medical...